主要:在DM或PM研究参与者中评价dazukibart的长期安全性.次要:以在本研究中接受dazukibart治疗的DM或PM研究参与者为对象,评价 dazukibart缓解肌肉(队列1和队列2)和皮肤(队列1)体征和症状的有效性;以在本研究中接受dazukibart治疗的DM或PM研究参与者为对象,评价dazukibart对患者报告结局的健康影响;以在本研究中接受dazukibart治疗的DM或PM研究参与者为对象,评价背景药物使用的变化;以在本研究中接受dazukibart治疗的DM或PM研究参与者为对象,评价dazukibart的挽救治疗规避效应;以在本研究中接受dazukibart治疗的DM或PM研究参与者为对象,评价dazukibart对肌炎特异性自身抗体的长期安全性;监测在本研究中接受dazukibart治疗且入组本研究之前ADA阳性的DM或PM研究参与者的免疫原性.探索:在本研究中接受dazukibart治疗的DM或PM研究参与者中评价dazukibart对肌肉表现持续时间的有效性.

开始日期2025-02-18

申办/合作机构

Pfizer Inc.

[+2]

NCT06698796

/ Recruiting临床3期

A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)

The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis [DM] or polymyositis [PM]).
Idiopathic inflammatory myopathies are a group of disorders that show inflammation of the muscles used for movement. There are several types of idiopathic inflammatory myopathies, including DM and PM.
DM and PM involve weakness of the muscles closest to the center of the body, such as the muscles of the hips, thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathies may find it difficult to climb stairs, get up from a seated position, or lift items above their head. People with DM can also have a skin rash.
These disorders negatively impact the quality of life and functioning of patients. In addition to the above, these disorders can affect how the lungs and heart work.
This study is seeking participants who took part in a DM and PM study with dazukibart before. Some participants will receive study medicine, and some participants will not receive study medicine and only complete safety follow-up.
The study medicine will be given as an intravenous (IV) infusion (directly into the veins). This takes about 1 hour, every 4 weeks, from Day 1 to Week 48 (about 12 months) of the study. This will be followed by a safety follow-up period that lasts about 4 months after the last infusion. Participants who receive study medicine will have about 18 study visits at the site over about 16 months.
There will also be participants enrolled in this study who will not receive study medicine. Such participants will only take part in safety follow-up visits as they do not want to or are not eligible to receive dazukibart. These participants will not receive study medicine and will have up to 4 study visits at the site every 4 weeks to complete safety follow-up.

开始日期2025-01-22

申办/合作机构

Pfizer Inc.

CTR20232664

/ Recruiting临床3期

一项在活动性特发性炎症性肌病受试者（包括活动性皮肌炎或多发性肌炎受试者）中评价 PF-06823859 疗效和安全性的 III 期、多中心、双盲、随机、安慰剂对照研究

主要：在活动性DM和PM成人受试者（≥18岁）中评价PF-06823859与安慰剂相比在改善肌肉症状方面的疗效。关键次要：在活动性DM和PM成人受试者（≥18岁）中评价PF-06823859与安慰剂相比在改善皮肤（队列1）及肌肉（队列1和2）体征和症状以及患者健康状况方面的疗效。其他次要：在指定时间点评价PF-06823859与安慰剂相比在改善TIS各类别、TISCSM各方面和皮肤状态方面的疗效。安全性次要：评价PF-06823859与安慰剂相比的安全性以及对DM或PM受试者中自身抗体形成的影响。探索性：在指定时间点评价PF-06823859与安慰剂相比在改善TIS各类别、TIS CSM各方面，皮肤状态，改善体力活动方面的疗效，在改善患者报告结局方面的经时疗效，激素减量和挽救治疗规避效应;通过皮肤照相评价PF-06823859改善皮肤状态的疗效;评价PF-06823859在改善肌肉耐力的疗效;分析PF-062823859的PK特征;确定靶点结合情况;确定IFN活性;估计PF-06823859对PROQoL和健康的经时影响;评价PF-06823859的免疫原性。

开始日期2023-11-10

申办/合作机构

Pfizer Inc.

[+2]

100 项与 Dazukibart 相关的临床结果

登录后查看更多信息

100 项与 Dazukibart 相关的转化医学

登录后查看更多信息

100 项与 Dazukibart 相关的专利（医药）

登录后查看更多信息

项与 Dazukibart 相关的文献（医药）

2025-01-01·LANCET

Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Article

作者: Femia, Alisa ; Fernandez, Anthony P ; Graham, Lauren V ; Hyde, Craig ; Rath, Natalie ; Christopher-Stine, Lisa ; Vincent, Michael S ; Peeva, Elena ; Fiorentino, David ; Aggarwal, Rohit ; Sloan, Abigail ; Musiek, Amy C M ; Chu, Myron ; Li, Xingpeng ; Vleugels, Ruth Ann ; Werth, Victoria P ; Salganik, Mikhail ; Beebe, Jean S ; Banfield, Christopher ; Sluzevich, Jason C ; Oemar, Barry ; Page, Karen M ; Neelakantan, Srividya ; Mangold, Aaron R ; Banerjee, Anindita ; Rieger, Kerri

BACKGROUND:

Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.

METHODS:

This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial was conducted at 25 university-based hospitals and outpatient sites in Germany, Hungary, Poland, Spain, and the USA. Adults aged 18-80 years with skin-predominant dermatomyositis were enrolled during stages 1, 2, and 2a, and had to have a Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A) score of 14 or more and at least one unsuccessful systemic treatment with standard of care; whereas those with muscle-predominant dermatomyositis were enrolled in stage 3 and had to have active moderate muscle involvement. Patients were randomly assigned using an interactive response technology system to dazukibart 600 mg or placebo in stage 1; dazukibart 600 mg, dazukibart 150 mg, or placebo in stage 2; dazukibart 600 mg then placebo, dazukibart 150 mg then placebo, placebo then dazukibart 600 mg, or placebo then dazukibart 150 mg in stage 2a; and dazukibart 600 mg then placebo or placebo then dazukibart 600 mg in stage 3. For stage 2a and stage 3, treatments were switched at week 12. Patients, investigators, outcome assessors, and funders were masked to the treatment assignment. Dazukibart and placebo were administered intravenously on day 1 every 4 weeks, up to and including week 8 (stages 1 and 2, and stages 2a and 3 for patients starting dazukibart), or on week 12 every 4 weeks, up to and including week 20 (stages 2a and 3 for patients who started placebo and switched to dazukibart). The primary outcome for the skin-predominant cohorts was the change from baseline in CDASI-A score at week 12 assessed in the full analysis set (FAS; stage 1) and the pooled skin FAS (stages 1, 2, and 2a), and safety in the muscle-predominant cohort. This study is registered with ClinicalTrials.gov, NCT03181893.

FINDINGS:

Between Jan 23, 2018, and Feb 23, 2022, 125 adults were assessed and 50 were excluded. 75 patients were randomly assigned and treated (15 to dazukibart 150 mg, 37 to dazukibart 600 mg, and 23 to placebo). Most patients were female (53 [93%] of 57 in the skin-predominant cohort vs 13 [72%] of 18 in the muscle-predominant cohort and four [7%] vs five [28%] were male). In the FAS in stage 1 at week 12, the mean change from baseline in CDASI-A for dazukibart 600 mg was -18·8 (90% CI -21·8 to -15·8; placebo-adjusted difference -14·8 [-20·3 to -9·4]; p<0·0001). In the pooled skin FAS at week 12, the mean change from baseline in CDASI-A for the dazukibart 600 mg group was -19·2 (-21·5 to -16·8; placebo-adjusted difference -16·3 [-20·4 to -12·1]; p<0·0001), whereas the dazukibart 150 mg group was -16·6 (-19·8 to -13·4; placebo-adjusted difference -13·7 [-18·3 to -9·0]; p<0·0001). Treatment-emergent adverse events occurred in 12 (80%) of 15 patients in the dazukibart 150 mg group versus 30 (81%) of 37 in the dazukibart 600 mg group versus 18 (78%) of 23 in the placebo group, with the most common being infections and infestations (two [13%] vs 12 [32%] vs seven [30%]). Four (11%) patients in the dazukibart 150 mg group and one (4%) in the placebo group reported serious adverse events. One patient in stage 3 received dazukibart 600 mg then placebo and died during follow-up due to haemophagocytic lymphohistiocytosis and macrophage activation syndrome.

INTERPRETATION:

Dazukibart resulted in a pronounced reduction in disease activity and was generally well tolerated, supporting IFNβ inhibition as a highly promising therapeutic strategy in adults with dermatomyositis.

FUNDING:

Pfizer.

2021-03-01·Clinical pharmacology in drug development

Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study

Article

作者: Pelletier, Kathleen ; Neelakantan, Srividya ; Messing, Dean ; Johnson, Kristen ; Berman, Gabe ; Tarabar, Sanela ; Rath, Natalie ; Cox, Lori ; Page, Karen ; Oemar, Barry ; Salganik, Mikhail

Abstract:

This double‐blind, randomized, placebo‐controlled, dose‐ascending, first‐in‐human study (NCT02766621) assessed the safety, tolerability, and pharmacokinetics (PK) of PF‐06823859, an anti–interferon β monoclonal antibody. Healthy subjects were randomized to single ascending doses (SADs) of intravenous PF‐06823859 30, 100, 300, 900, or 2000 mg or placebo; to multiple ascending doses (MADs) of subcutaneous PF‐06823859 100 or 300 mg or placebo (once every 2 weeks for a total of 3 doses); or to MAD of intravenous PF‐06823859 600 mg or placebo (once every 3 weeks or once every 4 weeks for a total of 2 doses). The incidence, severity, and causal relationship of adverse events (AEs) were assessed, along with immunogenicity and PK. In total, 62 subjects were randomized to treatment (SAD, n = 35; MAD, n = 27). There were 76 treatment‐emergent all‐causality AEs in the SAD (PF‐06823859: n = 25; placebo: n = 4) and MAD (PF‐06823859: n = 40; placebo: n = 7) cohorts. In the SAD cohorts, all treatment‐emergent all‐causality AEs were mild in severity; 4 AEs of moderate severity were identified in the MAD cohorts. No dose‐limiting AEs, serious AEs, treatment‐related discontinuations, dose reductions, or deaths occurred. PF‐06823859 exposure increased dose‐proportionally, with half‐life values ranging between 23 and 35 days. The estimated subcutaneous bioavailability was 43% to 44%. Immunogenicity incidence rates were low (antidrug antibodies, 12.5%; neutralizing antibodies, 2.1%). No immunogenically related clinical responses of concern were observed. In conclusion, PF‐06823859 demonstrated an acceptable safety, tolerability, and PK profile that supports clinical development for treating disorders associated with increased interferon β levels, such as dermatomyositis or systemic lupus erythematosus.

Arthritis & Rheumatology

Sustained IFN Signature Suppression with Anifrolumab in a SAVI patient Refractory to JAK Inhibitor and Dazukibart Therapy

Article

作者: Friend, Kip ; Kuhns, Douglas B. ; Rastegar, Andre ; Fink, Danielle ; Figg, William D. ; Colton, Ben ; Buehring, Bjoern ; Gaurav, Sachin ; Goldbach‐Mansky, Raphaela ; Alehashemi, Sara ; de Jesus, Adriana A ; Baumgardner, Alexi ; Peer, Cody J ; Arisa, Oluwatobi T.

Objective:

To report the efficacy and safety of interferon‐β (IFNβ) neutralizing monoclonal antibody (dazukibart), followed by treatment with anti‐IFNAR1 antibody (anifrolumab), in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who had vasculitic ulcers and systemic inflammation refractory to Janus kinase inhibition (JAKi).

Methods:

A SAVI patient with a de novo STING1 p.(Asn154Ser) mutation, a known pathogenic variant, and uncontrolled disease received twenty‐one doses of dazukibart under a compassionate use investigational new drug (IND) protocol, followed by treatment with the anti‐IFNAR1 antibody anifrolumab. Clinical and laboratory parameters, including wound healing, whole‐blood type I interferon (IFN I) signature, and safety markers were closely monitored throughout both treatment periods.

Results:

Despite initial reductions in C‐reactive protein (CRP) levels and IFN I scores following dazukibart administration, the patient experienced rebound inflammation and recurrent vasculitic lesions. Dazukibart dose adjustments failed to sustainably control IFN I signaling. Subsequent combination therapy of baricitinib and tocilizumab proved partially effective. Treatment with anifrolumab, an IFNα/β receptor (IFNAR1) blocker, in conjunction with tocilizumab, led to sustained suppression of IFN I scores, allowed discontinuation of JAKi, and resulted in significant improvement in vasculitic wounds.

Conclusion:

This case underscores the challenges in treating SAVI patients and highlights the utility of IFN I scores as a theragnostic biomarker. While high‐dose JAKi, and dazukibart failed to achieve sustained control of IFN I signaling, treatment with anifrolumab durably suppressed IFN scores and demonstrated promising efficacy, allowing investigation of the role of IFN I signaling in the disease pathogenesis of SAVI and other interferonopathies in future clinical trials.

项与 Dazukibart 相关的新闻（医药）

2024-11-19

·PRNewswire

Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and tissue damage across multiple organ systems, such as the skin, joints, kidneys, heart, and brain. The incidence of autoimmune diseases, including SLE, has been increasing globally, with a significant impact on demand for targeted and effective therapies. LAS VEGAS, Nov. 19, 2024 /PRNewswire/ -- DelveInsight's ' Systemic Lupus Erythematosus Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the systemic lupus erythematosus pipeline domain. Key Takeaways from the Systemic Lupus Erythematosus Pipeline Report DelveInsight's systemic lupus erythematosus pipeline report depicts a robust space with 120+ active players working to develop 140+ pipeline therapies for systemic lupus erythematosus treatment. Key systemic lupus erythematosus companies such as Roche, ImmuPharma, UCB, Idorsia Pharmaceuticals, Biogen, AbbVie, Bristol-Myers Squibb, Vera Therapeutics, Beijing Mabworks Biotech Co., Ltd., BeiGene, Jiangsu Renocell Biotech Company, AstraZeneca, Pfizer, Red de Terapia Celular, Kira Pharmacenticals (US), LLC., Jemincare, Galapagos NV, Alumis, argenx, Gilead Sciences, Novartis, Zenas Biopharma, Horizon Therapeutics, Provention Bio, Janssen Research & Development, Eli Lilly and Company, Medsenic, Sanofi, Merck KGaA, Resolve Therapeutics, ILTOO, Janssen, Alpine Immune Sciences, Kezar Life Sciences, Neovacs, Kangpu Biopharmaceuticals, Cartesian Therapeutics, Apellis Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Q32 Bio Inc., Conduit Pharmaceuticals, Miltenyi Biomedicine GmbH, Kyverna Therapeutics, ImmPACT Bio, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Gracell Biotechnologies (Shanghai) Co., Ltd., Cabaletta Bio, Tenet Medicines, Ascentage Pharma Group Inc., InnoCare, Eisai, Sorrento Therapeutics, Carna Bioscience, Yake Biotechnology, Equillium, Daiichi Sankyo Company, SinoMab Bioscience Ltd, Citryll BV, Sareum, Shanghai Junshi Biosciences, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Millennium Pharmaceuticals, Inc., Takeda, Synthekine, Hangzhou Sumgen Biotech Co., Ltd., Sana Biotechnology, Hoffmann-La Roche, Guangdong Ruishun Biotech Co., Ltd, Shanghai Ming Ju Biotechnology Co., Ltd., Autolus Limited, Nkarta, Inc., Luminary Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Ming Ju Biotechnology, IGM Biosciences, Inc., GlaxoSmithKline, Fate Therapeutics, Cugene Inc., Century Therapeutics, Inc., Cullinan Therapeutics Inc., Juno Therapeutics, Inc., EdiGene Inc., Atara Biotherapeutics, Annexon, Inc., Adicet Therapeutics, Bioray Laboratories, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Juventas Cell Therapy Ltd., Nanjing Bioheng Biotech Co., Ltd., Pregene ShenZhen Biotechnology, Artiva Bio, KeyMed Biosciences, IASO, JW Therapeutics, ROME Therapeutics, Ventus Therapeutics, Allosite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, LongBio Pharma, Amytrx Therapeutics, Corestem, Eliem Therapeutics, SinoMab Bioscience Ltd., and others are evaluating new systemic lupus erythematosus drugs to improve the treatment landscape. Promising systemic lupus erythematosus pipeline therapies such as Obinutuzumab, Lupuzor (IPP-201101), Dapirolizumab pegol, Cenerimod, BIIB059, Upadacitinib, Deucravacitinib, Atacicept, MIL62, Zanubrutinib, RY_SW01 cell injection|Basic treatment, Ravulizumab, Rapcabtagene autoleucel, PF-06823859, Mesenchymal stem cells (MSC), KP104, JMKX000189, Iptacopan, GLPG3667, ESK-001, Elsubrutinib, Efgartigimod alfa, Edecesertib, Ianalumab, Obexelimab (XmAb5871), Daxdilimab (VIB7734), PRV-3279, Nipocalimab, ABBV 599, NKTR-358 (LY3471851), Arscimed, SAR441344, Enpatoran, RSLV-132, Aldesleukin, Daratumumab, Branebrutinib, BMS-986256, ALPN-101, KZR-616, IFNα kinoid, KPG 818, Descartes-08, CFZ533, APL-2, ALXN2050, ADX-097, AZD1656, MB-CART19.1, KYV-101, IMPT-514, GR1603, GC012F Injection, CABA-201, Budoprutug, APG-2575, ICP-022, E6742, ALPN-303, AC0058, Mosunetuzumab, AS-0871, CD19/BCMA CAR T-cells, PF-06835375, EQ001 (Itolizumab), DS-7011a, SM03, CIT-013, SDC-1801, UBP1213, TQB3702, TAK-079, TAK-007, SYNCAR-001, SG301, SC291, RO7507062, RJMty19 (CD19-CAR-DNT cells), Relma-cel, PIT565, Obecabtagene autoleucel (obe-cel), NKX019, LMY-920, KK4277, JWCAR201, Imvotamab, GSK4527363, GSK4347859, FT819, CUG252, CNTY-101, CLN-978, CC-97540, Belantamab, ATHENA CAR-T ATA3219, ANX009, ADI-001, BRL-301, T-cell injection targeting CD19 chimeric antigen receptor, CNCT19, RD06-04, PRG-2311, PRG-1801, AlloNK, CM313, CT103A, JWCAR 029, Research program: endogenous reverse transcriptase inhibitors, VENT 03, ONT01, BCMA-CD19 cCAR T cells, CB-010, LP-005, AMTX 100, CE211AT15, TN-119, SN1011, QX002N, RSLV-145, Recombinant human plasma gelsolin, LN-008, TST 008, IBL 100s, and others are under different phases of systemic lupus erythematosus clinical trials. In October 2024, the FDA approved the investigational new drug (IND) application for Cullinan Therapeutics' CLN-978 to treat systemic lupus erythematosus (SLE). In September 2024, Cartesian Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). In September 2024, Caribou Biosciences announced that the U.S. Food and Drug Administration (FDA) had granted fast-track designation to CAR T-cell therapy CB-010 for systemic lupus erythematosus (SLE). In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe systemic lupus erythematosus. In August 2024, Conduit Pharmaceuticals announced they will be conducting a Phase IIa clinical trial to evaluate AZD1656 for the treatment of multiple autoimmune diseases, including systemic lupus erythematosus (SLE). In July 2024, the first individual received the therapy Descartes-08 to treat systemic lupus erythematosus. This therapy has been previously administered to patients with myasthenia gravis, a long-term autoimmune disorder characterized by muscle weakness. In February 2024, Idorsia Pharmaceuticals formed a major global research and development partnership with Viatris to advance and commercialize two Phase III assets, selatogrel and cenerimod, on a global scale. Request a sample and discover the recent advances in systemic lupus erythematosus treatment drugs @ Systemic Lupus Erythematosus Pipeline Report The systemic lupus erythematosus pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage systemic lupus erythematosus drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the systemic lupus erythematosus clinical trial landscape. Systemic Lupus Erythematosus Overview Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system mistakenly attacks healthy tissues in various parts of the body. The exact cause of SLE is unknown, but it is believed to result from a combination of genetic, environmental, and hormonal factors. Common triggers include infections, sunlight exposure, and certain medications. Women, particularly of childbearing age, are more commonly affected. Symptoms of SLE vary widely and can affect many organ systems, leading to a wide range of clinical presentations. Common symptoms include fatigue, joint pain, skin rashes, photosensitivity, and fever. More severe cases can affect the kidneys, heart, lungs, and central nervous system, potentially leading to life-threatening complications. Diagnosis of SLE is based on a combination of clinical features and laboratory tests. The antinuclear antibody (ANA) test is a common initial screening tool, but additional tests like anti-double stranded DNA (anti-dsDNA) and anti-Smith antibodies, as well as assessments of kidney and liver function, are often necessary. Diagnosis can be challenging because SLE symptoms often mimic those of other diseases. Treatment for SLE focuses on managing symptoms and preventing flares. Mild cases may be treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and antimalarial drugs like hydroxychloroquine. More severe cases may require corticosteroids, immunosuppressive drugs such as azathioprine, methotrexate, or newer biologics like belimumab. Lifestyle modifications, such as avoiding excessive sun exposure and managing stress, are also essential in controlling the disease. Find out more about systemic lupus erythematosus treatment drugs @ Drugs for Systemic Lupus Erythematosus Treatment A snapshot of the Systemic Lupus Erythematosus Pipeline Drugs mentioned in the report: Learn more about the emerging systemic lupus erythematosus pipeline therapies @ Systemic Lupus Erythematosus Clinical Trials Systemic Lupus Erythematosus Therapeutics Assessment The systemic lupus erythematosus pipeline report proffers an integral view of the systemic lupus erythematosus emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Systemic Lupus Erythematosus Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Cell death inhibitors, Cell death stimulants, Immunomodulators, CD40 ligand inhibitors, Sphingosine 1 phosphate receptor modulators, Calcineurin inhibitors, Immunosuppressants, Janus kinase 1 inhibitors, TYK2 kinase inhibitors, B cell activating factor inhibitors, Tumour necrosis factor ligand superfamily member 13 inhibitors Key Systemic Lupus Erythematosus Companies: Roche, ImmuPharma, UCB, Idorsia Pharmaceuticals, Biogen, AbbVie, Bristol-Myers Squibb, Vera Therapeutics, Beijing Mabworks Biotech Co., Ltd., BeiGene, Jiangsu Renocell Biotech Company, AstraZeneca, Pfizer, Red de Terapia Celular, Kira Pharmacenticals (US), LLC., Jemincare, Galapagos NV, Alumis, argenx, Gilead Sciences, Novartis, Zenas Biopharma, Horizon Therapeutics, Provention Bio, Janssen Research & Development, Eli Lilly and Company, Medsenic, Sanofi, Merck KGaA, Resolve Therapeutics, ILTOO, Janssen, Alpine Immune Sciences, Kezar Life Sciences, Neovacs, Kangpu Biopharmaceuticals, Cartesian Therapeutics, Apellis Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Q32 Bio Inc., Conduit Pharmaceuticals, Miltenyi Biomedicine GmbH, Kyverna Therapeutics, ImmPACT Bio, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Gracell Biotechnologies (Shanghai) Co., Ltd., Cabaletta Bio, Tenet Medicines, Ascentage Pharma Group Inc., InnoCare, Eisai, Sorrento Therapeutics, Carna Bioscience, Yake Biotechnology, Equillium, Daiichi Sankyo Company, SinoMab Bioscience Ltd, Citryll BV, Sareum, Shanghai Junshi Biosciences, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Millennium Pharmaceuticals, Inc., Takeda, Synthekine, Hangzhou Sumgen Biotech Co., Ltd., Sana Biotechnology, Hoffmann-La Roche, Guangdong Ruishun Biotech Co., Ltd, Shanghai Ming Ju Biotechnology Co., Ltd., Autolus Limited, Nkarta, Inc., Luminary Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Ming Ju Biotechnology, IGM Biosciences, Inc., GlaxoSmithKline, Fate Therapeutics, Cugene Inc., Century Therapeutics, Inc., Cullinan Therapeutics Inc., Juno Therapeutics, Inc., EdiGene Inc., Atara Biotherapeutics, Annexon, Inc., Adicet Therapeutics, Bioray Laboratories, PersonGen BioTherapeutics (Suzhou) Co., Ltd., Juventas Cell Therapy Ltd., Nanjing Bioheng Biotech Co., Ltd., Pregene ShenZhen Biotechnology, Artiva Bio, KeyMed Biosciences, IASO, JW Therapeutics, ROME Therapeutics, Ventus Therapeutics, Allosite Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, LongBio Pharma, Amytrx Therapeutics, Corestem, Eliem Therapeutics, SinoMab Bioscience Ltd., and others. Key Systemic Lupus Erythematosus Pipeline Therapies: Obinutuzumab, Lupuzor (IPP-201101), Dapirolizumab pegol, Cenerimod, BIIB059, Upadacitinib, Deucravacitinib, Atacicept, MIL62, Zanubrutinib, RY_SW01 cell injection|Basic treatment, Ravulizumab, Rapcabtagene autoleucel, PF-06823859, Mesenchymal stem cells (MSC), KP104, JMKX000189, Iptacopan, GLPG3667|Placebo, ESK-001, Elsubrutinib, Efgartigimod alfa, Edecesertib, Ianalumab, Obexelimab (XmAb5871), Daxdilimab (VIB7734), PRV-3279, Nipocalimab, ABBV 599, NKTR-358 (LY3471851), Arscimed, SAR441344, Enpatoran, RSLV-132, Aldesleukin, Daratumumab, Branebrutinib, BMS-986256, ALPN-101, KZR-616, IFNα kinoid, KPG 818, Descartes-08, CFZ533, APL-2, ALXN2050, ADX-097, AZD1656, MB-CART19.1, KYV-101, IMPT-514, GR1603, GC012F Injection, CABA-201, Budoprutug, APG-2575, ICP-022, E6742, ALPN-303, AC0058, Mosunetuzumab, AS-0871, CD19/BCMA CAR T-cells, PF-06835375, EQ001 (Itolizumab), DS-7011a, SM03, CIT-013, SDC-1801, UBP1213, TQB3702, TAK-079, TAK-007, SYNCAR-001, SG301, SC291, RO7507062, RJMty19 (CD19-CAR-DNT cells), Relma-cel, PIT565, Obecabtagene autoleucel (obe-cel), NKX019, LMY-920, KK4277, JWCAR201, Imvotamab, GSK4527363, GSK4347859, FT819, CUG252, CNTY-101, CLN-978, CC-97540, Belantamab, ATHENA CAR-T ATA3219, ANX009, ADI-001, BRL-301, T-cell injection targeting CD19 chimeric antigen receptor, CNCT19, RD06-04, PRG-2311, PRG-1801, AlloNK, CM313, CT103A, JWCAR 029, Research program: endogenous reverse transcriptase inhibitors, VENT 03, ONT01, BCMA-CD19 cCAR T cells, CB-010, LP-005, AMTX 100, CE211AT15, TN-119, SN1011, QX002N, RSLV-145, Recombinant human plasma gelsolin, LN-008, TST 008, IBL 100s, and others. Dive deep into rich insights for new drugs for systemic lupus erythematosus treatment, visit @ Systemic Lupus Erythematosus Drugs Table of Contents For further information on the systemic lupus erythematosus pipeline therapeutics, reach out @ Systemic Lupus Erythematosus Treatment Drugs Related Reports Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Systemic Lupus Erythematosus Epidemiology Systemic Lupus Erythematosus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted SLE epidemiology in the 7MM. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, NOVARTIS, CABALETTA BIO, among others. Lupus Nephritis Pipeline Lupus Nephritis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including Inflection Biosciences, Equillium, Roche, Horizon Therapeutics, BeiGene, Janssen Research & Development, ImmPACT Bio, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床2期快速通道细胞疗法

2024-04-20

·蒲公英Ouryao

宇宙大药厂关掉其著名的创新研发部门

转自：MedTrend医趋势（有删减）从去年开始，辉瑞一直在践行削减成本策略。 4月17日，辉瑞宣布关闭其著名的创新研发部门——治疗创新中心（CTI），该团队旨在通过与外部研究人员的合作来促进新药研发。辉瑞治疗创新中心（CTI）近年来最具影响力的成绩，或许是孵化出Telavant公司被罗氏收购。 2023年10月，罗氏宣布以71亿美元预付价格收购Roivant与辉瑞的合资公司Telavant，获得其重磅核心产品溃疡性结肠炎候选治疗药物TL1A抗体RVT-3101，且后续具有选择权共同开发新一代IL-23p40/TL1A双抗。此外，罗氏还将支付1.5亿美元的近期里程碑付款，总交易金额高达72.5亿美元。辉瑞的一位发言人告诉媒体，公司决定关闭CTI的实验室，并将某些CTI项目嵌入辉瑞研发部门的其他研究单元。该发言人证实，辉瑞做出这一决定是“全公司成本调整计划的一部分”。发言人表示：辉瑞在CTI之外还有许多其他学术合作，并将继续致力于寻求学术与产业合作，以弥合早期科学发现与转化为潜在新疗法之间的差距。 CTI成立于2010年，旨在为全国各地的医生科学家与制药公司更广泛的研发资源牵线搭桥。该创新中心的实验室分布于美国四个城市，其团队与研究人员一起就“加速将概念转化为可行性疗法”展开合作。从CTI项目中诞生的一些药物除了辉瑞于2022年移交给Roivant的抗TL1A项目；也是辉瑞公司用于治疗皮肌炎和多发性肌炎的IFN-β3期药物dazukibart的来源，这项研究来自哈佛医学院和布里格姆妇女医院的科学家。 CTI隶属于由UweSchoenbeck博士领导的新兴科学与创新(ES&I)团队。ES&I团队特别关注早期科学，而非成熟临床阶段产品的许可交易。去年，辉瑞发布了规模达35亿美元的成本削减计划，该计划引发了辉瑞公司此后的一系列裁员。在其以430亿美元收购了ADC巨头Seagen之后，目标是在2024年将辉瑞重新塑造成一家全球领先的肿瘤药企。

并购抗体药物偶联物

2023-08-29

·医药观澜

辉瑞超20亿美元合作开发！创新蛋白降解疗法在中国启动3期临床，针对乳腺癌！

▎药明康德内容团队报道中国药物临床试验登记与信息公示平台官网公示，辉瑞（Pfizer）在中国启动了蛋白降解靶向嵌合体vepdegestrant片的3期临床，拟用于ER+/HER2-乳腺癌一线治疗。Vepdegestrant最初由Arvinas公司开发，2021年，辉瑞与Arvinas公司达成超20亿美元的合作，以共同开发和商业化该产品。此外，辉瑞还在中国启动了人源化干扰素β（IFN-β）抗体PF-06823859的3期临床，拟用于治疗活动性特发性炎症性肌病。Vepdegestrant作用机制：蛋白降解靶向嵌合体适应症：ER+/HER2-乳腺癌一线治疗截图来源：中国药物临床试验登记与信息公示平台Vepdegestrant（ARV-471、PF-07850327）是Arvinas公司开发的一种可利用的蛋白降解靶向嵌合体，旨在特异性靶向和降解雌激素受体（ER），用于治疗早期和局部晚期或转移性ER+（ER阳性）/HER2-（HER2阴性）乳腺癌患者。Vepdegestrant的潜力已在临床试验中得到初步验证。1期临床试验数据显示，无论肿瘤表达野生型ER还是突变型ER，vepdegestrant最高可将ER水平降低90%。在34名可以评估临床获益的患者中，临床获益率为41%。根据中国药物临床试验登记与信息公示平台，辉瑞本次在中国启动的是国际多中心3期VERITAC-3研究。试验的主要目的为：证明在既往未接受过任何针对晚期疾病的系统性抗癌治疗的ER阳性、HER2阴性晚期乳腺癌受试者中，vepdegestrant联合CDK4/6抑制剂哌柏西利治疗在延长无进展生存期（PFS）方面优于芳香化酶抑制剂来曲唑联合哌柏西利治疗。该研究中国主要研究者为中国医学科学院肿瘤医院徐兵河教授，研究拟在中国境内入组177人，在国际入组1180人。值得一提的是，除了本次启动用于乳腺癌一线治疗的VERITAC-3研究，辉瑞此前还在中国启动了vepdegestrant的国际多中心3期VERITAC-2研究，该研究旨在既往针对晚期疾病、以内分泌为基础的治疗后疾病进展的ER阳性、HER2阴性晚期乳腺癌受试者中比较该药与雌激素受体（ER）拮抗剂氟维司群的疗效和安全性。VERITAC-2研究的中国主要研究者为复旦大学附属肿瘤医院胡夕春教授。据悉，Arvinas公司和辉瑞公司将在2023年欧洲肿瘤内科学会（ESMO）年会上公布vepdegestrant的最新临床研究数据，其中就包括了3期VERITAC-2研究。PF-06823859作用机制：人源化干扰素β抗体适应症：活动性特发性炎症性肌病截图来源：中国药物临床试验登记与信息公示平台PF-06823859是辉瑞开发的一种人源化干扰素β（IFN-β）抗体，可阻断干扰素β1成纤维细胞，拟开发用于治疗皮肌炎和狼疮。辉瑞本次在中国启动的是一项3期、多中心、双盲、随机、安慰剂对照研究，研究旨在活动性特发性炎症性肌病受试者（包括活动性皮肌炎或多发性肌炎受试者）中评价PF-06823859的疗效和安全性。活动性特发性炎症性肌病包括一系列以炎症和肌肉无力为特征的自身免疫性疾病，包括了皮肌炎（DM）和多发性肌炎（PM）。其中，皮肌炎会引起皮肤改变和肌无力，随着时间的推移，肌肉无力会越来越严重，并可能导致关节僵硬和肌肉萎缩。在皮肌炎患者的血液和皮肤中，干扰素β（IFN-β）的表达水平显著升高，而且IFN-β激活的基因表达信号与患者皮肤症状的严重程度相关。根据辉瑞公开资料，在针对皮肌炎患者的2期临床试验中，PF-06823859不但显著抑制IFN-β介导的基因表达，而且降低了疾病临床活动的指标。本次辉瑞在中国启动的3期研究主要目的是在活动性DM和PM成人受试者中评价PF-06823859与安慰剂相比在改善肌肉症状方面的疗效。试验关键次要目的是在活动性DM和PM成人受试者中，评价PF-06823859与安慰剂相比在改善皮肤（队列1）及肌肉（队列1和2）体征和症状以及患者健康状况方面的疗效。该研究由中国医学科学院北京协和医院曾小峰教授担任中国主要研究者。参考资料:[1]中国药物临床试验登记与信息公示平台官网. Retrieved Aug 28，2023. From http://www.chinadrugtrials.org.cn/clinicaltrials.searchlist.dhtml[2] Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Retrieved May 08，2023. From https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-upcoming-vepdegestrant-arv-471[3] Third Quarter 2021 Earnings Teleconference. Retrieved November 2, 2021, from https://s21.q4cdn.com/317678438/files/doc_financials/2021/q3/Q3-2021-Earnings-Charts-FINAL.pdf本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床3期临床2期临床失败

100 项与 Dazukibart 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肌炎	临床3期	美国	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	中国	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	日本	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	阿根廷	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	比利时	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	保加利亚	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	法国	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	德国	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	匈牙利	Pfizer Inc.	2023-05-20
皮肌炎	临床3期	印度	Pfizer Inc.	2023-05-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05192200 (CTgov)	临床2期	皮肌炎	24	PF-06823859 (PF-06823859 600mg: Skin Cohort)	襯構構齋窪膚膚糧築憲 = 膚壓築衊窪願襯網網齋窪簾顧鏇觸壓齋繭壓觸 (顧遞淵壓淵淵鑰醖選願, 餘衊襯製獵糧獵蓋選窪 ~ 顧壓構遞鏇獵窪鑰齋淵) 更多	-	2025-02-06
				PF-06823859 (PF-06823859 600mg: Muscle Cohort)	襯構構齋窪膚膚糧築憲 = 獵簾獵衊衊淵遞遞鹹鏇窪簾顧鏇觸壓齋繭壓觸 (顧遞淵壓淵淵鑰醖選願, 餘衊繭簾餘範壓網構遞 ~ 齋鏇鹽鏇構壓憲築網夢) 更多
NCT05037409 (CTgov)	临床1期	-	13	Placebo	壓顧獵構衊衊壓鹽餘簾 = 膚鹹築艱餘糧鹹繭鑰構製憲襯觸鏇築鏇蓋鏇遞 (鹽蓋艱艱簾遞獵選襯顧, 鏇築顧廠鏇網鏇獵鏇獵 ~ 壓衊遞鹹鬱窪構壓壓衊) 更多	-	2023-12-15
NCT03181893 (EADV2023)	临床2期	皮肌炎 IFN β	72	PF-06823859 150 mg	壓衊顧壓壓夢範醖網糧(繭觸襯遞積衊築觸遞醖) = 鹽衊衊簾選繭鬱範顧鹹網獵繭選壓簾鹹觸積鹽 (選鹽顧選簾製餘艱蓋繭 ) 更多	-	2023-10-11
				PF-06823859 600 mg	壓衊顧壓壓夢範醖網糧(繭觸襯遞積衊築觸遞醖) = 鬱壓艱窪窪壓築齋鬱願網獵繭選壓簾鹹觸積鹽 (選鹽顧選簾製餘艱蓋繭 ) 更多
NCT02766621 (Pubmed) 人工标引	临床1期	-	62	PF 06823859	醖顧廠醖淵願獵窪衊壓(構積鏇窪願觸網糧憲製) = No deaths occurred. 簾鹹遞淵願網構繭齋鹽 (夢壓壓鏇壓壓鹹網膚鏇 ) 更多	积极	2021-03-01
				Placebo